Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
33.4M
-
Shares change
-
+1.45M
-
Total reported value, excl. options
-
$359M
-
Value change
-
+$12.5M
-
Put/Call ratio
-
1.4
-
Number of buys
-
84
-
Number of sells
-
-53
-
Price
-
$10.77
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2019
179 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q3 2019.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.4M shares
of 49.6M outstanding shares and own 67.25% of the company stock.
Largest 10 shareholders include Partner Fund Management, L.P. (3.69M shares), VANGUARD GROUP INC (3.5M shares), STATE STREET CORP (2.97M shares), FRED ALGER MANAGEMENT, LLC (1.67M shares), Sarissa Capital Management LP (1.42M shares), Palo Alto Investors LP (1.41M shares), Nuveen Asset Management, LLC (1.16M shares), MACQUARIE GROUP LTD (1.12M shares), GOLDMAN SACHS GROUP INC (986K shares), and FEDERATED INVESTORS INC /PA/ (848K shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.